Zepbound (tirzepatide 2.5mg-15mg) is FDA-approved for chronic weight management, offering even greater weight loss than Wegovy in clinical trials. Despite strong clinical evidence, coverage remains limited and denials are common.
Zepbound Coverage Status (2025)
- Many commercial plans are beginning to cover Zepbound
- Medicare does not cover Zepbound for weight loss
- Employer plans vary widely — check your plan's formula
- Some plans cover with prior authorization and documented medical necessity
Clinical Evidence
- SURMOUNT-1: 22.5% mean weight loss at highest dose (72 weeks)
- SURMOUNT-2: 14.7% weight loss in patients with type 2 diabetes
- SURMOUNT-3: 26.6% weight loss with lifestyle intervention
- SURMOUNT-4: Weight regain prevention data
Appeal Strategy
- Document BMI and weight-related comorbidities
- Reference FDA approval and clinical trial data
- Cite obesity as a chronic disease (AMA, WHO, ICD-10 E66)
- Document failed prior weight management attempts
- If plan excludes weight loss drugs, argue medical necessity exception
- Reference cardiovascular benefit data from Mounjaro trials
Cost Considerations
Retail price: approximately $1,060/month. Eli Lilly offers savings programs for eligible commercially insured patients.